Diadema Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Diadema Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,300	Closed	-$7.95M	–	194
2025 Q4	$7.95M	Sell	10,300 -19,860	-66%	-$13.5M	1.37%	23
2025 Q3	$17M	Buy	30,160 +24,553	+438%	+$13.9M	4.34%	2
2025 Q2	$2.94M	Sell	5,607 -24,221	-81%	-$13.5M	0.9%	34
2025 Q1	$18.9M	Buy	+29,828	New	+$20.5M	4.94%	3

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Diadema Partners's REGN Position: Q1 2026 in Review

Diadema Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 10,300 shares — an estimated $7.95M sold.

Diadema Partners first reported a position in REGN in Q1 2025 and held it in 4 quarters. The position peaked at $18.9M in Q1 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Diadema Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 10,300 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.95M.
Diadema Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Diadema Partners's Regeneron Pharmaceuticals position peaked at $18.9M in Q1 2025.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.